Incyte announced positive results from its Phase 1/2 study of latarcibart for Von Willebrand Disease (VWD). The company presented this data at the ISTH 2026 Congress. The trial involved 16 patients with all major types of the inherited bleeding disorder. The investigational antibody proved safe and well-tolerated.
A once-monthly subcutaneous dose of latarcibart led to a median 81% reduction in the annualized bleeding rate (ABR). This reduction occurred across all patient and bleed types. For patients switching from existing intravenous therapies, bleed reductions ranged from 75% to 100%. Latarcibart recently received Breakthrough Therapy designation from the FDA. The drug is now enrolling for a pivotal Phase 3 trial.